Opinion|Videos|March 21, 2025
Latest Advances in the Management of Advanced NSCLC with ALK or ROS1 Mutations
Panelists discuss how the 5-year follow-up data from the CROWN trial support lorlatinib as a frontline treatment for ALK-positive non–small cell lung cancer NSCLC with brain metastasis. For frontline therapy, starting at full dose is preferred, adjusting if needed. Post progression, lorlatinib can be continued or combined with other agents. Biomarker testing for ROS1 is essential, with recent data (TRIDENT-1 trial) favoring lorlatinib for ROS1-positive central nervous system (CNS) involvement. Novel agents like taletrectinib and zidesamtinib from TRUST-I/II and ARROS-1 trials show promise in expanding treatment options for ROS1-positive NSCLC.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Briefly comment on the 5-year follow-up data from the CROWN trial and discuss how these findings inform your first-line treatment approach and in managing ALK-positive NSCLC with brain metastasis. (Solomon BJ, et al. J Clin Oncol. 2024;42(29):3400-3409.)
- Do you prefer starting patients at the full dose with subsequent dose reductions if necessary, or initiating at a lower dose and titrating upward as tolerated?
- For patients receiving lorlatinib in the frontline setting, how do you manage treatment following disease progression?
- Briefly discuss your approach to biomarker testing for ROS1 alterations and how recent data inform your treatment decisions in this space.
- How do the latest data from TRIDENT-1 trial inform your treatment approach for patients with ROS1 alterations and CNS involvement? (Drilon A, et al. NEJM. 2024;390:118-131.)
- Briefly comment on the TRUST-I/II (Perol, M et al. ESMO 2024. Abs 1289P) and ARROS-1 (Besse B, et al. ESMO 2024. Abs 1256MO) trials. Where do you see these novel agents (eg, taletrectinib and zidesamtinib) fitting in the treatment paradigm?
Advertisement
Related to this article
An NDA seeks FDA approval of savolitinib plus osimertinib for EGFR-mutated NSCLC with MET overexpression or amplification after EGFR TKI therapy.
Daiichi Sankyo and Merck withdrew the I-DXd BLA in ES-SCLC after FDA discussions found phase 2 IDeate-Lung01 data insufficient for accelerated approval.
The addition of the β-catenin pathway inhibitor tegavivint to osimertinib produced deep responses in a phase 1b study in first-line EGFR-mutated NSCLC.
The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The phase 3 REZILIENT3 trial met its primary end point at a pre-specified interim analysis, with a median PFS of 14.5 months and a 65.0% ORR.
The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
China's NMPA Approves Pirtobrutinib Across CLL
3
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
4
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
5